Frontiers in Endocrinology (Jul 2022)
Prediabetes Induces More Severe Acute COVID-19 Associated With IL-6 Production Without Worsening Long-Term Symptoms
- Icaro Bonyek-Silva,
- Icaro Bonyek-Silva,
- Icaro Bonyek-Silva,
- Icaro Bonyek-Silva,
- Thiago Cerqueira-Silva,
- Thiago Cerqueira-Silva,
- Sara Nunes,
- Sara Nunes,
- Antônio Fernando Araújo Machado,
- Márcio Rivison Silva Cruz,
- Blenda Pereira,
- Blenda Pereira,
- Leilane Estrela,
- Jéssica Silva,
- Jéssica Silva,
- Ananda Isis,
- Aldina Barral,
- Aldina Barral,
- Aldina Barral,
- Pablo Rafael Silveira Oliveira,
- Ricardo Khouri,
- Ricardo Khouri,
- C. Henrique Serezani,
- Cláudia Brodskyn,
- Cláudia Brodskyn,
- Cláudia Brodskyn,
- Juliana Ribeiro Caldas,
- Juliana Ribeiro Caldas,
- Juliana Ribeiro Caldas,
- Manoel Barral-Netto,
- Manoel Barral-Netto,
- Manoel Barral-Netto,
- Viviane Boaventura,
- Viviane Boaventura,
- Natalia Machado Tavares,
- Natalia Machado Tavares,
- Natalia Machado Tavares
Affiliations
- Icaro Bonyek-Silva
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Icaro Bonyek-Silva
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Icaro Bonyek-Silva
- Federal Institute of Education, Science and Technology Baiano, Xique-Xique, Brazil
- Icaro Bonyek-Silva
- Faculty of Santa Cruz of Bahia (FSC), Nursing School, Itaberaba, Brazil
- Thiago Cerqueira-Silva
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Thiago Cerqueira-Silva
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Sara Nunes
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Sara Nunes
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Antônio Fernando Araújo Machado
- School of Health Sciences, Salvador University (UNIFACS), Salvador, Brazil
- Márcio Rivison Silva Cruz
- School of Health Sciences, Salvador University (UNIFACS), Salvador, Brazil
- Blenda Pereira
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Blenda Pereira
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Leilane Estrela
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Jéssica Silva
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Jéssica Silva
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Ananda Isis
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Aldina Barral
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Aldina Barral
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Aldina Barral
- National Institute of Science and Technology (INCT), Institute of Investigation in Immunology (iii-INCT), São Paulo, Brazil
- Pablo Rafael Silveira Oliveira
- Institute of Biological Sciences, Federal University of Bahia (IBio-UFBA), Salvador, Brazil
- Ricardo Khouri
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Ricardo Khouri
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- C. Henrique Serezani
- Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
- Cláudia Brodskyn
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Cláudia Brodskyn
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Cláudia Brodskyn
- National Institute of Science and Technology (INCT), Institute of Investigation in Immunology (iii-INCT), São Paulo, Brazil
- Juliana Ribeiro Caldas
- School of Health Sciences, Salvador University (UNIFACS), Salvador, Brazil
- Juliana Ribeiro Caldas
- Critical Care Unit, São Rafael Hospital – Rede d’Or, Salvador, Brazil
- Juliana Ribeiro Caldas
- 0Bahiana School of Medicine and Public Health – EBMSP, Campus Brotas, Salvador, Brazil
- Manoel Barral-Netto
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Manoel Barral-Netto
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Manoel Barral-Netto
- National Institute of Science and Technology (INCT), Institute of Investigation in Immunology (iii-INCT), São Paulo, Brazil
- Viviane Boaventura
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Viviane Boaventura
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Natalia Machado Tavares
- Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Natalia Machado Tavares
- Medical School, Federal University of Bahia (FAMEB-UFBA), Salvador, Brazil
- Natalia Machado Tavares
- National Institute of Science and Technology (INCT), Institute of Investigation in Immunology (iii-INCT), São Paulo, Brazil
- DOI
- https://doi.org/10.3389/fendo.2022.896378
- Journal volume & issue
-
Vol. 13
Abstract
AimsPre-existing conditions, such as age, hypertension, obesity, and diabetes, constitute known risk factors for severe COVID-19. However, the impact of prediabetes mellitus (PDM) on COVID-19 severity is less clear. This study aimed to evaluate the influence of PDM in the acute and long-term phases of COVID-19.Materials and methodsWe compared inflammatory mediators, laboratory and clinical parameters and symptoms in COVID-19 patients with prediabetes (PDM) and without diabetes (NDM) during the acute phase of infection and at three months post-hospitalization.ResultsPatients with PDM had longer hospital stays and required intensive care unit admission more frequently than NDM. Upon hospitalization, PDM patients exhibited higher serum levels of interleukin 6 (IL-6), which is related to reduced partial pressure of oxygen (PaO2) in arterial blood, oxygen saturation (SpO2) and increased COVID-19 severity. However, at three months after discharge, those with PDM did not exhibit significant alterations in laboratory parameters or residual symptoms; however, PDM was observed to influence the profile of reported symptoms.ConclusionsPDM seems to be associated with increased risk of severe COVID-19, as well as higher serum levels of IL-6, which may constitute a potential biomarker of severe COVID-19 risk in affected patients. Furthermore, while PDM correlated with more severe acute-phase COVID-19, no long-term worsening of sequelae was observed.
Keywords